Clinical Trial Q&A
Lentiviral vector expresses protein for up to four years in trial.
Phase IIA trial shows potential of its neuroprotective properties for retinal disease.
Phase II trial shows Clearside’s CLS-TA safe and effective in noninfectious uveitis.
By inhibiting complement factor C3, Apellis bets it can prevent inflammation in advanced dry AMD
This biological agent targets mutations in genes that mediate visual transduction.
A deeper dive into how this Tie-2 activator stabilizes the retinal vasculature.
A closer look at combination therapy and CNV.
Lead investigator provides details on parallel trials of lampalizumab.